Matches in Wikidata for { <http://www.wikidata.org/entity/Q65387491> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- Q65387491 description "clinical trial" @default.
- Q65387491 description "ensayu clínicu" @default.
- Q65387491 description "klinisch onderzoek" @default.
- Q65387491 description "клінічне випробування" @default.
- Q65387491 name "Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg" @default.
- Q65387491 name "Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg" @default.
- Q65387491 type Item @default.
- Q65387491 label "Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg" @default.
- Q65387491 label "Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg" @default.
- Q65387491 prefLabel "Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg" @default.
- Q65387491 prefLabel "Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg" @default.
- Q65387491 P1132 Q65387491-8EE7E27A-3446-44B0-B354-116A58D4E33F @default.
- Q65387491 P1476 Q65387491-7FEBE282-0F9A-4369-B19E-726ED34DB293 @default.
- Q65387491 P17 Q65387491-11029F59-8077-4094-A396-28F9D7DDD5E8 @default.
- Q65387491 P17 Q65387491-14B6E415-C29F-4593-9ADE-88F7154F89DB @default.
- Q65387491 P17 Q65387491-2FF84C63-43F4-4B21-AF1F-847CF470F1E9 @default.
- Q65387491 P17 Q65387491-42CE4889-DF8B-4515-82FB-B92F2F7A0DC2 @default.
- Q65387491 P17 Q65387491-8EA67931-E488-4E93-A6BF-515E7831E4D9 @default.
- Q65387491 P17 Q65387491-A5940C6C-E7A2-4F4D-AB5E-083EA1E71AFC @default.
- Q65387491 P17 Q65387491-BFAC4D4A-7C2E-4AB6-B9B0-EB704D71752D @default.
- Q65387491 P17 Q65387491-D8A899A7-BF61-458B-A441-58368731CCE7 @default.
- Q65387491 P17 Q65387491-F3BA3382-5754-4782-B394-3ABE9D92922F @default.
- Q65387491 P17 Q65387491-F7671C29-6E71-49C7-AABE-47561029EE0A @default.
- Q65387491 P2899 Q65387491-4D74D965-4CF3-402C-BE11-44B5E6DC56BA @default.
- Q65387491 P3098 Q65387491-BA65A378-DBEB-4191-819E-2BCD9F263580 @default.
- Q65387491 P31 Q65387491-0888B5F2-21C2-47AF-A6C8-CE23BC27FA37 @default.
- Q65387491 P4135 Q65387491-480A716D-D935-422E-9305-7DA153594B8F @default.
- Q65387491 P4844 Q65387491-59BA2CF1-3B4A-4287-93BD-E11159F95344 @default.
- Q65387491 P4844 Q65387491-6FA330E1-FC91-4B02-AFB9-2A949CC3CC7A @default.
- Q65387491 P580 Q65387491-D08ADF80-859D-46FE-A420-D2147DD2422E @default.
- Q65387491 P582 Q65387491-0B904AB7-BF24-447C-8E3C-4CE1343E7597 @default.
- Q65387491 P6099 Q65387491-69DD90C4-5038-49E6-A1FE-88A49972ABA6 @default.
- Q65387491 P8363 Q65387491-7B241DC8-8CA4-4E8A-9337-83E41CFF9305 @default.
- Q65387491 P921 Q65387491-E400D34E-ED28-4D96-8871-3D2F6ECB6597 @default.
- Q65387491 P1132 "+1979" @default.
- Q65387491 P1476 "A Double Blind, Randomised, 3-Arm Parallel Group, Multicentre, 8-Week, Phase III Study to Assess Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) /HCT 32/12.5mg and 32/25mg vs. CC 32mg Alone in Patients With Inadequate BP Control on Monotherapy With CC 32mg" @default.
- Q65387491 P17 Q142 @default.
- Q65387491 P17 Q145 @default.
- Q65387491 P17 Q183 @default.
- Q65387491 P17 Q191 @default.
- Q65387491 P17 Q212 @default.
- Q65387491 P17 Q34 @default.
- Q65387491 P17 Q35 @default.
- Q65387491 P17 Q36 @default.
- Q65387491 P17 Q37 @default.
- Q65387491 P17 Q55 @default.
- Q65387491 P2899 "+20" @default.
- Q65387491 P3098 "NCT00383929" @default.
- Q65387491 P31 Q30612 @default.
- Q65387491 P4135 "+80" @default.
- Q65387491 P4844 Q27075664 @default.
- Q65387491 P4844 Q415970 @default.
- Q65387491 P580 "2006-09-01T00:00:00Z" @default.
- Q65387491 P582 "2007-08-01T00:00:00Z" @default.
- Q65387491 P6099 Q42824827 @default.
- Q65387491 P8363 Q78089383 @default.
- Q65387491 P921 Q1304270 @default.